Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Accounts Payables (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed Accounts Payables for 12 consecutive years, with $619000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accounts Payables rose 11.33% year-over-year to $619000.0, compared with a TTM value of $619000.0 through Sep 2025, up 11.33%, and an annual FY2024 reading of $1.3 million, down 46.96% over the prior year.
  • Accounts Payables was $619000.0 for Q3 2025 at Lisata Therapeutics, down from $782000.0 in the prior quarter.
  • Across five years, Accounts Payables topped out at $2.4 million in Q4 2023 and bottomed at $556000.0 in Q3 2024.
  • Average Accounts Payables over 3 years is $1.1 million, with a median of $782000.0 recorded in 2025.
  • The sharpest move saw Accounts Payables tumbled 57.62% in 2024, then grew 11.33% in 2025.
  • Year by year, Accounts Payables stood at $2.4 million in 2023, then tumbled by 46.96% to $1.3 million in 2024, then plummeted by 51.79% to $619000.0 in 2025.
  • Business Quant data shows Accounts Payables for LSTA at $619000.0 in Q3 2025, $782000.0 in Q2 2025, and $602000.0 in Q1 2025.